Northwell’s Feinstein Institutes Researcher Alex C. Spyropoulos Receives Prestigious Fulbright U.S. Scholar Recognition
Alex C. Spyropoulos, an internationally recognized authority in thrombosis and blood clotting disorders, has been awarded a prestigious Fulbright U.S. Scholar distinction for the 2026–2027 academic year. The honor, conferred by the U.S. Department of State in partnership with the Fulbright Foreign Scholarship Board, recognizes his outstanding contributions to medical science and his commitment to advancing global collaboration in healthcare research and education.
Dr. Spyropoulos currently serves as a professor at the Institute of Health System Science within the Feinstein Institutes for Medical Research, as well as a professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. His selection for the Fulbright program represents both a personal achievement and a broader acknowledgment of his influence in the field of anticoagulation and thrombotic disease management. Through this program, he will engage in international research and academic exchange, contributing to the advancement of global health initiatives and strengthening cross-border scientific collaboration.
The Fulbright Program is widely regarded as the flagship educational exchange initiative of the United States government. Established in 1946, the program was designed to promote mutual understanding between nations through scholarly and cultural exchange. Over the decades, it has grown into one of the most respected international programs of its kind, with nearly 450,000 participants worldwide. Each year, more than 800 U.S. scholars travel abroad under the program to teach, conduct research, or collaborate with international institutions across more than 160 countries.
Fulbright alumni represent a distinguished network of global leaders and innovators, including Nobel laureates, Pulitzer Prize winners, MacArthur Fellows, and heads of state. By joining this community, Dr. Spyropoulos becomes part of a legacy that has significantly shaped global academic, scientific, and policy landscapes. The program is funded primarily by the U.S. federal government, with additional support from host countries, universities, corporations, and foundations, reflecting its broad international reach and collaborative foundation.
Expressing his gratitude, Dr. Spyropoulos described the award as both an honor and a unique opportunity to expand the boundaries of medical science through international engagement. He emphasized the importance of sharing knowledge and fostering collaboration, particularly in the field of thrombosis and anticoagulation, where global cooperation can lead to improved patient outcomes. His Fulbright experience is expected to focus on advancing research, exchanging clinical expertise, and contributing to educational initiatives that benefit healthcare systems worldwide.
Dr. Spyropoulos is widely recognized for his pioneering work in anticoagulation therapy, particularly in the prevention and treatment of venous thromboembolism (VTE), a serious condition that includes deep vein thrombosis and pulmonary embolism. His research has also been instrumental in shaping clinical understanding of the appropriate use of direct oral anticoagulants (DOACs), as well as the perioperative management of patients receiving antithrombotic therapy. These contributions have had a direct impact on clinical guidelines and everyday medical practice, improving safety and efficacy in the management of clotting disorders.
His professional affiliations further underscore his leadership in the field. Dr. Spyropoulos is a Fellow of several prestigious organizations, including the American College of Physicians, the American College of Chest Physicians, the International Academy of Clinical and Applied Thrombosis/Haemostasis, and the Royal College of Physicians of Canada. These affiliations reflect his global reputation and ongoing commitment to advancing clinical excellence.
Throughout his career, Dr. Spyropoulos has played a leading role in numerous landmark clinical trials that have shaped modern approaches to anticoagulation therapy. Among these is the BRIDGE trial, funded by the National Institutes of Health, which examined strategies for managing anticoagulation in patients undergoing surgical procedures. He also contributed to the PAUSE trial, which provided critical insights into the safe use of direct oral anticoagulants around the time of surgery.
In addition, Dr. Spyropoulos was involved in the MARINER trial, which evaluated extended thromboprophylaxis in hospitalized medical patients, and the PREVENT-HD trial, which explored strategies to prevent clotting complications in patients with COVID-19. His leadership extended to the HEP-COVID trial, where he served as principal investigator, helping determine optimal anticoagulation strategies for hospitalized COVID-19 patients. He also contributed to the CORE-19 registry, one of the largest datasets examining thromboembolic outcomes in patients hospitalized with COVID-19.
Collectively, these studies have had a profound impact on clinical practice, particularly during the COVID-19 pandemic, when thrombotic complications emerged as a significant concern. Dr. Spyropoulos’ work has helped guide clinicians in managing these risks, contributing to improved patient outcomes during a global health crisis. His extensive body of research includes more than 330 peer-reviewed publications, reflecting both the depth and breadth of his contributions to medical science.
Kevin J. Tracey, MD, President and CEO of the Feinstein Institutes, praised Dr. Spyropoulos for his dedication and impact, noting that his selection as a Fulbright Scholar is a testament to his commitment to advancing medical knowledge and fostering global collaboration. Such recognition highlights not only his individual achievements but also the importance of continued investment in scientific research and international partnerships.
In addition to his research accomplishments, Dr. Spyropoulos remains actively engaged in advancing clinical discourse. Recently, he co-authored an editorial in the New England Journal of Medicine, addressing treatment strategies for patients with intermediate-risk pulmonary embolism. The editorial discussed findings from the HI-PEITHO trial, which investigated the use of ultrasound-facilitated, catheter-directed thrombolysis (CDT). This innovative approach was shown to significantly reduce adverse outcomes such as pulmonary embolism-related mortality and cardiac complications, while maintaining a favorable safety profile with no increase in major bleeding risk.
The findings highlighted in this work represent a meaningful advancement in the management of pulmonary embolism, offering clinicians a more effective and safer therapeutic option for patients with this potentially life-threatening condition. Such contributions exemplify Dr. Spyropoulos’ ongoing commitment to translating research into practical solutions that improve patient care.
In summary, Dr. Alex C. Spyropoulos’ selection as a Fulbright U.S. Scholar reflects his exceptional contributions to thrombosis research and his dedication to advancing global health through collaboration and innovation. As he embarks on this new chapter, his work is expected to further strengthen international partnerships, enhance medical education, and drive progress in the understanding and treatment of thrombotic diseases worldwide.
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research.
We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program.
